MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Medpace Holdings, Inc. has faced significant stock price decline following disappointing second quarter 2024 financial results, raising concerns about potential violations of federal securities laws and unlawful business practices [2][1]. Financial Performance - On July 22, 2024, Medpace reported second quarter 2024 financial results that significantly missed market expectations [2]. - The company experienced disproportionately high cancellations in June 2024, attributed to factors such as reprioritization, impaired sponsor liquidity, and a large pharmaceutical acquisition that led to work being shifted to a preferred provider [2]. Stock Market Reaction - Following the earnings announcement, Medpace's stock price dropped by $79.88, or 18.3$357.30 per share on July 23, 2024, resulting in losses for investors [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Medpace on behalf of its stockholders regarding possible violations of federal securities laws and other unlawful business practices [1].